Catalent introduces Peel-ID safe storage label to improve storage and retrieval of patient kits
Peel-ID greatly reduces the risk of human error resulting from the incorrect kit being pulled from inventory due to illegible handwriting or incorrectly transposed numbers.
Catalent Pharma Solutions has introduced its Peel-ID label, a new standard for clinical supply labeling that helps to reduce the risk of patients receiving the incorrect medication at clinical sites.
The patent-ending clinical label comprises a permanent portion, and a peel-off label containing the patient kit identifier, which can be removed by site personnel and affixed elsewhere on the patient kit to better facilitate storage, inventory management and quick retrieval. Peel-ID labels are designed and printed in-house by Catalent and are available in a variety of standard sizes and designs to fit most patient kits.
The Peel-ID label was developed in response to some sites manually writing kit identification numbers on an unlabeled side of a package, because the label is obscured due to the way the kits are stored. With a Peel-ID label, the risk of human error resulting from the incorrect kit being pulled from inventory due to illegible handwriting or incorrectly transposed numbers is greatly reduced.
“Our clinical site liaisons recognized the potential for harm from this practice and engaged our employees to develop an innovative and practical solution,” said Esther Sadler-Williams, Global Director Strategic Development and Innovation at Catalent. “Peel-ID will now be our standard recommendation to customers for all patient kits packaged by Catalent, reducing risks to patient safety.”
”The innovative Peel-ID label gives clinical sites increased flexibility in their storage options whilst being confident that an integral, approved label can be used on any surface of the kit,” added Dr. Samantha Carmichael, Lead Pharmacist Clinical Trials, Clinical Research & Development, NHS Greater Glasgow & Clyde. “This could streamline the dispensing process for patients at sites that hold a lot of stock, and those that undertake a manual transcription process can be confident in a reduced risk of errors.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance